标题:Substance P and fibrotic diseases
作者:Peng, Lei; Agogo, George O.; Guo, Jianqiang; Yan, Ming
作者机构:[Peng, Lei; Guo, Jianqiang] Shandong Univ, Hosp 2, Dept Gastroenterol, Jinan, Shandong, Peoples R China.; [Agogo, George O.] Yale Univ, Med Sch, Dep 更多
通讯作者:Guo, JQ;Yan, M
通讯作者地址:[Guo, JQ]Shandong Univ, Hosp 2, Dept Gastroenterol, Jinan, Shandong, Peoples R China;[Yan, M]Shandong Univ, Qilu Hosp, Dept Hepatol & Gastroenterol, J 更多
来源:NEUROPEPTIDES
出版年:2019
卷:76
DOI:10.1016/j.npep.2019.101941
关键词:Substance P; NK-1R; Fibrotic disease
摘要:Substance P (SP) is an undecapeptide encoding the tachykinin 1 (TAC1) gene and belongs to the tachykinin family. SP is widely distributed in the central nervous system and the peripheral nervous system. SP is also produced by nonneuronal cells, such as inflammatory cells and endothelial cells. The biological activities of SP are mainly regulated through the high-affinity neurokinin 1 receptor (NK-1R). The SP/NK-1R system plays an important role in the molecular bases of many human pathophysiologic processes, such as pain, infectious and inflammatory diseases, and cancer. In addition, this system has been implicated in fibrotic diseases and processes such as wound healing, myocardial fibrosis, bowel fibrosis, myelofibrosis, renal fibrosis, and lung fibrosis. Recently, studies have shown that SP plays an important role in liver fibrosis and that NK-1R antagonists can inhibit the progression of fibrosis. NK-1R receptor antagonists could provide clinical solutions for fibrotic diseases. This review summarizes the structure and function of SP and its involvement in fibrotic diseases.
收录类别:SCOPUS;SCIE
WOS核心被引频次:1
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067980450&doi=10.1016%2fj.npep.2019.101941&partnerID=40&md5=6341966dd41dbb3862a2e21efc98aa75
TOP